ITCI: 13% | Intra-Cellular Therapies shares are trading higher after the company announced topline results from its second Phase 3 trial evaluating Lumateperone as adjunctive therapy for patients with major depressive disorder, meeting primary and key secondary endpoints.
LZB: 13% | La-Z-Boy shares are trading higher following better-than-expected Q4 earnings.
ASNS: 178% | Actelis Announces Agreement With Carahsoft For Carahsoft To Serve As Its Public Sector Distributor